Xuebijing injection, a Chinese patent medicine, against severe pneumonia: Current research progress and future perspectives.
10.1016/j.joim.2023.08.004
- Author:
Mei ZHANG
1
;
Rui ZHENG
2
,
3
;
Wen-Jing LIU
4
;
Jun-Ling HOU
1
;
Yu-Lei YANG
1
;
Hong-Cai SHANG
5
Author Information
1. School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
2. Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China
3. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton L8S 4K1, Canada.
4. Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
5. Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China. Electronic address: shanghongcai@foxmail.com.
- Publication Type:Research Support, Non-U.S. Gov't
- Keywords:
Clinical trial;
Pneumonia, bacterial;
Pneumonia, viral;
Severe pneumonia;
Treatment mechanism;
Xuebijing injection
- MeSH:
Humans;
Nonprescription Drugs;
Shock, Septic/drug therapy*;
Sepsis/drug therapy*;
Endotoxins;
Anticoagulants/therapeutic use*
- From:
Journal of Integrative Medicine
2023;21(5):413-422
- CountryChina
- Language:English
-
Abstract:
Severe pneumonia is one of the most common infectious diseases and the leading cause of sepsis and septic shock. Preventing infection, balancing the patient's immune status, and anti-coagulation therapy are all important elements in the treatment of severe pneumonia. As multi-target agents, Xuebijing injection (XBJ) has shown unique advantages in targeting complex conditions and saving the lives of patients with severe pneumonia. This review outlines progress in the understanding of XBJ's anti-inflammatory, endotoxin antagonism, and anticoagulation effects. From the hundreds of publications released over the past few years, the key results from representative clinical studies of XBJ in the treatment of severe pneumonia were selected and summarized. XBJ was observed to effectively suppress the release of pro-inflammatory cytokines, counter the effects of endotoxin, and assert an anticoagulation effect in most clinical trials, which are consistent with experimental studies. Collectively, this evidence suggests that XBJ could play an important and expanding role in clinical medicine, especially for sepsis, septic shock and severe pneumonia. Please cite this article as: Zhang M, Zheng R, Liu WJ, Hou JL, Yang YL, Shang HC. Xuebijing injection, a Chinese patent medicine, against severe pneumonia: Current research progress and future perspectives. J Integr Med. 2023; 21(5): 413-422.
